Shares Homepage - BSE Sensex, NSE Nifty, Latest Prices, Live News, Company Search, Result Annoucements, Company News, Top stories, Gainers Losers, Top Performers, Market Commentary, Live Quotes, Bulk Deals
India's preferred Personal finance destination
Home Shares News Centre F&O Mutual Funds IPO Portfolio Commodity Loans Financial Planning Insurance About Us
Markets Companies Research Industries E-Mail Page
Wealth Tracker      Tax Corner NRI Centre Chat Masala Feedback
my Last 5 Scrips
Company BSE Price(Rs) % Chg
Tata Stl 489.35 3.73
Tata Pow 93.75 3.19
Hindalco 163.20 1.75
Ntpc Ltd 149.95 1.90
Gail 529.15 3.83
Clear All Clear Last
Shares
NSE Live
Nifty Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
BSE Live
BSE30 Live Prices
Live Quotes
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
IPO Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Discussion Forum
Research
Research Reports
Sector Watch
Economy Watch
Snapshot-Ipca Laboratories Limited
Ipca Laboratories Limited
Sector:Pharmaceuticals Pharmaceuticals - Bulk Drugs and Formulations
BSE:524494NSE:IPCALABBloomberg:IPCA@INReuters:IPCA.BO
Market Lot: 1Face Value: 2ISIN Demat: INE571A01020
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
01-OCT-14 IPCA Laboratories, a Mumbai-based drugmaker, announced that the company has acquired as a going concern on slump sale basis the high potency oral solid dosage formulations manufacturing unit situated at sector III, Pithampur, Dhar (Madhya Pradesh). 25-AUG-14 CRISIL has reaffirmed `AA/Stable` ratings on the bank facilities and debt programmes of IPCA Laboratories (IPCA). The ratings continue to reflect IPCA`s well-diversified business...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
Angel Broking maintains 'Buy' on Ipca Laboratories  -IRIS 22-Sep-14
Previous

More


Brief Financials (in Rs. Mn.)Detailed Quarterly
Period ending (months)31-Mar-2014 (12)31-Mar-2013 (12)31-Mar-2012 (12)
Net sales 31817.6027388.2022992.40
Other Income214.30186.60129.20
Total Income32031.9027574.8023121.60
Cost of goods sold24295.9021571.3018158.90
OPBDIT7736.006003.504962.70
PAT4773.703313.902801.70
Gross Block---
Equity capital252.40252.40252.30
EPS (Rs.)37.8326.2722.23
DPS (Rs.)---
BV (Rs.)---
P/E range (x)13.01 - 23.9712.19 - 21.5810.36 - 15.83
Debt / Equity (x)---
Operating margin (% of OI)24.221.821.5
Net margin (% of OI)14.912.012.1
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
48, Kandivli Industrial Estate
Kandivli (West)
Mumbai
Maharashtra-400 067
PHONE
(022) 6647 4444
FAX
(022) 2868 6613
 
Board of Directors
Board Meetings
Date Purpose
10-NOV-14 Quarterly Results
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer